The KBI and Selexis co-location will expand biopharmaceutical development and manufacturing capabilities to serve the global demand for novel therapies.

GENEVA, July 06, 2022--(BUSINESS WIRE)--KBI Biopharma SA (KBI) and Selexis SA, both JSR Life Sciences companies, held a joint ribbon-cutting ceremony yesterday at their new state-of-the-art facility in Geneva, Switzerland. Designed to directly serve the increased demand for biopharmaceutical drug development and manufacturing in Europe, the facility will support an integrated, end-to-end process of Selexis’ cell line development (CLD) services along with KBI’s contract development and manufacturing services for industry clients throughout the immediate region and beyond.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005082/en/

KBI Biopharma and Selexis ribbon cutting at their new state-of-the-art facility in Geneva, Switzerland, Tuesday, July 5, 2022 (from left to right: Mark Lutgen, KBI Biopharma, VP of Global Engineering; Mario Rodriguez, Mayor, Plan-les-Ouates; Fabienne Fischer, State Councilor and Head of the Department of the Economy and Employment; Mark W. Womack, KBI Biopharma and Selexis, Chief Executive Officer; Tim Lowery, President, JSR Life Sciences) (Photo: Business Wire)

As demand for innovative biologics and effective biosimilars to treat cancer, infectious diseases, and autoimmune diseases continue to rise in Europe and around the world, developing and manufacturing these and other therapeutics, remains complex and time-consuming. By co-locating in one facility, KBI and Selexis will deliver trusted, streamlined, and cost-effective solutions to help clients confidently advance their investigational therapies.

"The opening of our Geneva facility last month was a major milestone for KBI and Selexis, and we are excited to come together today and commemorate this great achievement," said Mark W. Womack, CEO of KBI and Selexis. "KBI and Selexis have a long history of success together. Our collaboration has accelerated more than 60 drug development programs in Europe and worldwide. Integrating Selexis’ world-renowned CLD services with KBI’s process development innovation and excellence, as well as clinical and commercial manufacturing experience provides our clients with seamless, cost-effective, and reliable development and manufacturing for their products. Our aim has always been to help our clients bring novel and effective therapies to the clinic and the market faster. This facility will help advance that mission."

The ~94,000 square-foot facility will house new laboratories to support Selexis’ unique technical cell line workflows and KBI’s process development and cGMP manufacturing and quality control with a suite of analytical testing laboratories and cGMP single-use manufacturing trains. The expansion will generate over 300 positions in development, operations, and quality assurance. The ribbon-cutting, held on July 5, was attended by the following:

Luca Bolliger, VP of the Swiss Biotech Association and President of the Swiss Biotech Success Stories Jury

Mario Rodriguez, Mayor of Plan-les-Ouates

Fabienne Fischer, State Councilor - Member of the Geneva government, Head of the economy and employment department (DEE)

"I am delighted with the development of KBI and Selexis' activities in Geneva, which contributes to the development of the life sciences sector in Geneva and reinforces our local ecosystem," said Councilor Fischer. "It also demonstrates the potential and attractiveness of our region."

KBI Biopharma SA is a wholly-owned subsidiary of KBI Biopharma, Inc., and a JSR Life Sciences company. KBI Biopharma is a leading global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps clients advance drug candidates into the clinic and beyond. KBI serves its global clients with multiple locations in Europe and the USA. www.kbibiopharma.com

Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global client partners have utilized Selexis technologies to advance more than 160 drug candidates in preclinical and clinical development and manufacture ten commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220706005082/en/

KBI Biopharma Company Inquiries Aruna Mor KBI Biopharma, Inc. amor@kbibiopharma.com

Selexis SA Company Inquiries Maria-Pilar Gimenez Selexis SA maria-pilar.gimenez@selexis.com

KBI Biopharma Media Inquiries Blair Ciecko CG Life bciecko@cglife.com

Selexis SA Media Inquiries Mike Beyer Sam Brown Inc. mikebeyer@sambrown.com

The tech billionaire keeps plowing millions into this asset class.

Anyone positioning their portfolio for a recession could be making a big mistake.

Berkshire Hathaway's quarterly 13F filing won't tell you about the Oracle of Omaha's $6.3 billion hidden portfolio.

Now that we’re into the second half of 2022, with the Independence Day holiday behind us, we can take stock of the changes that the last six months have brought. And those changes have been dramatic. As this year got started, the S&P 500 was coming off of a 27% annual gain. Today, the index is down 20%, putting it into a bear market. The losses have been broad-based, and have left many otherwise sound equities languishing at low prices. It’s a circumstance that has a lot of unhappy investors won

The uber-wealthy investor is thrifty with everything from his breakfast to his house.

In its Chapter 11 bankruptcy filing on Tuesday, New Jersey-based Voyager estimated that it had more than 100,000 creditors and somewhere between $1 billion and $10 billion in assets, and liabilities worth the same value. Chapter 11 bankruptcy procedures put a hold on all civil litigation matters and allow companies to prepare turnaround plans while remaining operational. "The prolonged volatility and contagion in the crypto markets over the past few months, and the default of Three Arrows Capital on a loan from the company's subsidiary, Voyager Digital, LLC, require us to take deliberate and decisive action now," Voyager Chief Executive Officer Stephen Ehrlich said in a statement.

Yahoo Finance Live anchors discuss Mark Zuckerberg's economic warning to Meta employees, the average monthly care payment crossing the $700 mark, and AMC announcing $5 Tuesdays through the end of October.

Stocks are set to veer south post holiday, following earlier optimism over reports President Joe Biden may lower tariffs on some Chinese goods to help ease the inflation sting. There isn’t much to explain the moodiness of stocks, which logged gains on Friday, but weekly losses on worries about a recession spurred on by rising U.S. interest rates. In the U.S., mortgage applications are down 28% from their peak, new home sales are off 17% and housing starts down 13%.

Hecla Mining Company (NYSE: HL) (Hecla) and Alexco Resource Corp. (NYSE American: AXU) (TSX: AXU) (Alexco) are pleased to announce a definitive agreement for Hecla to acquire all of the outstanding common shares of Alexco that Hecla does not already own. Each outstanding common share of Alexco will be exchanged for 0.116 of a share of Hecla common stock implying consideration of US$0.47 per Alexco common share and a premium of 23% based on the companies' 5-day volume weighted average price on th

(Bloomberg) -- The Federal Reserve will unveil details of what policy makers debated last month that may shed light on how they view the near-term path for interest rates amid surging inflation and signs of a slowing economy.Most Read from BloombergNatural Gas Soars 700%, Becoming Driving Force in the New Cold WarCiti Says Oil May Collapse to $65 by the Year-End on RecessionOil Plummets Below $100 as Recession Risks Come to ForefrontUS Wants Dutch Supplier to Stop Selling Chipmaking Gear to Chin

HOUSTON (Reuters) -More than 5 million barrels of oil that were part of a historic U.S. emergency reserves release to lower domestic fuel prices were exported to Europe and Asia last month, according to data and sources, even as U.S. gasoline and diesel prices hit record highs. The export of crude and fuel is blunting the impact of the moves by U.S. President Joe Biden to lower record pump prices. Biden on Saturday renewed a call for gasoline suppliers to cut their prices, drawing criticism from Amazon founder Jeff Bezos.

(Bloomberg) -- Bridgewater Associates posted a 32% return for its flagship hedge fund through the first half of 2022 as it benefited from increased market volatility, according to a person familiar with the performance.Most Read from BloombergNatural Gas Soars 700%, Becoming Driving Force in the New Cold WarCiti Says Oil May Collapse to $65 by the Year-End on RecessionOil Plummets Below $100 as Recession Risks Come to ForefrontUS Wants Dutch Supplier to Stop Selling Chipmaking Gear to ChinaUkrai

‘My credit-union credit card allows me to make a balance transfer at 0% financing with no fee once a year.’

He also predicts a ‘more significant pullback’ if this one thing happens.

Minutes from the June meeting of the Fed and JOLTs job openings will give investors their latest chance to revise expectations of monetary policy.

One of the costs of converting a traditional IRA to a Roth IRA is how much you will pay in taxes. In some cases, those taxes can be a heavy burden, especially if you have been diligent in building up … Continue reading → The post Doing a Roth Conversion Like This Can Minimize Your Taxes appeared first on SmartAsset Blog.

(Bloomberg) -- Crypto broker Voyager Digital Ltd. filed for Chapter 11 bankruptcy protection just weeks after getting a lifeline from billionaire Sam Bankman-Fried’s Alameda Research, citing market volatility and the collapse of a hedge fund it had lent money to. Most Read from BloombergNatural Gas Soars 700%, Becoming Driving Force in the New Cold WarCiti Says Oil May Collapse to $65 by the Year-End on RecessionOil Plummets Below $100 as Recession Risks Come to ForefrontUS Wants Dutch Supplier

IKHAIL KLIMENTYEV/Sputnik/AFP via Getty ImagesRussian President Vladimir Putin’s key ally Belarusian leader Alexander Lukashenko has started hinting at what may be next in Russia’s war, and it doesn’t sound pretty.Lukashenko claimed this weekend that he thinks it’s time for Europe to face a “moral cleansing.”“The time has come for the forgetful Europe to give itself a moral cleansing,” Lukashenko said, without going into further detail about what that would entail, according to BelTA.Lukashenko

The biggest home price drops are likely in Canada and New Zealand, while only a 5% decline is forecast in the U.S.

Zuckerberg has chosen his moment well: the crypto sector is currently going through an unprecedented crisis of confidence marked by a fall in the price of digital currencies. Bitcoin, the king of cryptocurrencies, has lost 71.3% of its value since its all-time high on November 10, according to data from CoinGecko. Ether, the second cryptocurrency by market value, is down 78% from its November all-time high as well.